The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: A case series

Se Hyun Kim, Dong Chung Jung, Yong Min Ahn, Yong Sik Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Poor adherence to clozapine treatment represents an important problem in clinical practice because additional useful treatment options are unavailable. Although switching to risperidone long-acting injection (RLAI) has been recommended for those with compliance problems, this medication has been found to be less suitable for patients who previously received clozapine. Based on the suggested beneficial effects of RLAI, such as higher rates of treatment continuation and patient satisfaction, and the possible effectiveness of oral risperidone augmentation, it seems worthwhile to try RLAI augmentation for clozapine non-adherence. In this article, we present the cases of four patients with schizophrenia undergoing combined treatment with RLAI and clozapine for more than one year after multiple relapses related to clozapine non-adherence. Durations and frequencies of hospitalizations markedly declined after RLAI augmentation. Indeed, three patients receiving RLAI and clozapine for 1.2-3.5 years were never hospitalized during this period. The lengths of hospitalizations before and after augmenting with RLAI were 54.7 ± 33.1 and 4.2 ± 4.2 days/year, respectively. Participants also showed great improvements in social skills. These findings suggest the possible beneficial effects of RLAI augmentation in cases of clozapine nonadherence. However, controlled clinical trials are necessary to confirm whether RLAI augmentation represents a useful treatment option for patients who have not adhered to clozapine treatment.

Original languageEnglish
Pages (from-to)981-986
Number of pages6
JournalJournal of Psychopharmacology
Volume24
Issue number7
DOIs
StatePublished - 1 Jul 2010

Fingerprint

Risperidone
Clozapine
Schizophrenia
Injections
Hospitalization
Therapeutics
Medication Adherence
Controlled Clinical Trials
Patient Satisfaction
Recurrence

Keywords

  • Antipsychotic
  • Augmentation
  • Clozapine
  • Risperidone long-acting injection
  • Schizophrenia

Cite this

@article{b1858c1f611b4ce281c95c94c8812584,
title = "The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: A case series",
abstract = "Poor adherence to clozapine treatment represents an important problem in clinical practice because additional useful treatment options are unavailable. Although switching to risperidone long-acting injection (RLAI) has been recommended for those with compliance problems, this medication has been found to be less suitable for patients who previously received clozapine. Based on the suggested beneficial effects of RLAI, such as higher rates of treatment continuation and patient satisfaction, and the possible effectiveness of oral risperidone augmentation, it seems worthwhile to try RLAI augmentation for clozapine non-adherence. In this article, we present the cases of four patients with schizophrenia undergoing combined treatment with RLAI and clozapine for more than one year after multiple relapses related to clozapine non-adherence. Durations and frequencies of hospitalizations markedly declined after RLAI augmentation. Indeed, three patients receiving RLAI and clozapine for 1.2-3.5 years were never hospitalized during this period. The lengths of hospitalizations before and after augmenting with RLAI were 54.7 ± 33.1 and 4.2 ± 4.2 days/year, respectively. Participants also showed great improvements in social skills. These findings suggest the possible beneficial effects of RLAI augmentation in cases of clozapine nonadherence. However, controlled clinical trials are necessary to confirm whether RLAI augmentation represents a useful treatment option for patients who have not adhered to clozapine treatment.",
keywords = "Antipsychotic, Augmentation, Clozapine, Risperidone long-acting injection, Schizophrenia",
author = "Kim, {Se Hyun} and Jung, {Dong Chung} and Ahn, {Yong Min} and Kim, {Yong Sik}",
year = "2010",
month = "7",
day = "1",
doi = "10.1177/0269881109348174",
language = "English",
volume = "24",
pages = "981--986",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "7",

}

The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine : A case series. / Kim, Se Hyun; Jung, Dong Chung; Ahn, Yong Min; Kim, Yong Sik.

In: Journal of Psychopharmacology, Vol. 24, No. 7, 01.07.2010, p. 981-986.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine

T2 - A case series

AU - Kim, Se Hyun

AU - Jung, Dong Chung

AU - Ahn, Yong Min

AU - Kim, Yong Sik

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Poor adherence to clozapine treatment represents an important problem in clinical practice because additional useful treatment options are unavailable. Although switching to risperidone long-acting injection (RLAI) has been recommended for those with compliance problems, this medication has been found to be less suitable for patients who previously received clozapine. Based on the suggested beneficial effects of RLAI, such as higher rates of treatment continuation and patient satisfaction, and the possible effectiveness of oral risperidone augmentation, it seems worthwhile to try RLAI augmentation for clozapine non-adherence. In this article, we present the cases of four patients with schizophrenia undergoing combined treatment with RLAI and clozapine for more than one year after multiple relapses related to clozapine non-adherence. Durations and frequencies of hospitalizations markedly declined after RLAI augmentation. Indeed, three patients receiving RLAI and clozapine for 1.2-3.5 years were never hospitalized during this period. The lengths of hospitalizations before and after augmenting with RLAI were 54.7 ± 33.1 and 4.2 ± 4.2 days/year, respectively. Participants also showed great improvements in social skills. These findings suggest the possible beneficial effects of RLAI augmentation in cases of clozapine nonadherence. However, controlled clinical trials are necessary to confirm whether RLAI augmentation represents a useful treatment option for patients who have not adhered to clozapine treatment.

AB - Poor adherence to clozapine treatment represents an important problem in clinical practice because additional useful treatment options are unavailable. Although switching to risperidone long-acting injection (RLAI) has been recommended for those with compliance problems, this medication has been found to be less suitable for patients who previously received clozapine. Based on the suggested beneficial effects of RLAI, such as higher rates of treatment continuation and patient satisfaction, and the possible effectiveness of oral risperidone augmentation, it seems worthwhile to try RLAI augmentation for clozapine non-adherence. In this article, we present the cases of four patients with schizophrenia undergoing combined treatment with RLAI and clozapine for more than one year after multiple relapses related to clozapine non-adherence. Durations and frequencies of hospitalizations markedly declined after RLAI augmentation. Indeed, three patients receiving RLAI and clozapine for 1.2-3.5 years were never hospitalized during this period. The lengths of hospitalizations before and after augmenting with RLAI were 54.7 ± 33.1 and 4.2 ± 4.2 days/year, respectively. Participants also showed great improvements in social skills. These findings suggest the possible beneficial effects of RLAI augmentation in cases of clozapine nonadherence. However, controlled clinical trials are necessary to confirm whether RLAI augmentation represents a useful treatment option for patients who have not adhered to clozapine treatment.

KW - Antipsychotic

KW - Augmentation

KW - Clozapine

KW - Risperidone long-acting injection

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=77953800875&partnerID=8YFLogxK

U2 - 10.1177/0269881109348174

DO - 10.1177/0269881109348174

M3 - Article

C2 - 19942641

AN - SCOPUS:77953800875

VL - 24

SP - 981

EP - 986

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 7

ER -